On this page
Diamond-Blackfan anaemia
This condition typically appears in infancy, causing severe anaemia that requires regular treatment. Affected individuals may also develop physical differences and face an increased risk of certain cancers. Around 5 to 7 people per million are born with Diamond-Blackfan anaemia in the UK.
Overview
Diamond-Blackfan anaemia (DBA) belongs to a group of conditions known as inherited bone marrow failure syndromes. The hallmark feature is an inability of the bone marrow to manufacture adequate numbers of red blood cells, even though other blood cell types are usually produced normally. Most children with DBA present within their first year of life with pallor, fatigue, and poor feeding due to profound anaemia. Without intervention, the oxygen-carrying capacity of the blood falls to dangerously low levels.
Research suggests that DBA arises from defects in the cellular machinery responsible for building ribosomes, the protein factories found in every cell [PMID:18326823]. When ribosome production is disrupted, red blood cell precursors in the bone marrow fail to mature properly, leading to the characteristic anaemia. Approximately half of affected individuals also have physical features such as thumb abnormalities, cleft palate, or distinctive facial appearance, though the spectrum is broad and many people with DBA have no physical anomalies beyond the blood disorder.
Although Diamond-Blackfan anaemia is rare, it has been intensively studied because understanding how ribosome defects lead to specific tissue failure has wider implications for cell biology. Families affected by DBA benefit from coordinated specialist care and access to genetic counselling through NHS clinical genetics services.
Symptoms & clinical features
The dominant clinical feature of Diamond-Blackfan anaemia is severe anaemia that typically becomes apparent between birth and one year of age. Infants may appear unusually pale, feed poorly, and fail to gain weight at the expected rate. Fatigue and breathlessness during feeding are common. Some affected babies are identified before symptoms emerge if routine blood tests show markedly reduced red blood cell counts.
Beyond anaemia, a proportion of individuals with DBA experience developmental differences affecting various body systems. The range and severity of these features varies considerably between affected individuals, and some people with DBA have no outward physical differences beyond the blood disorder. Growth patterns may also be affected in some cases.
Video: Genetics 101
Affected organs
The primary target in Diamond-Blackfan anaemia is the bone marrow, specifically the erythroid lineage responsible for red blood cell production. Red cell precursors fail to mature beyond an early stage, whilst white blood cell and platelet production typically remain intact, at least initially. This selective failure distinguishes DBA from other bone marrow failure syndromes where multiple cell lines are affected from the outset.
Long-term complications can include an elevated risk of certain malignancies, particularly myelodysplastic syndrome, acute myeloid leukaemia, and some solid tumours, reflecting the underlying cellular stress associated with ribosomal dysfunction.
Risks & severity
The severity of Diamond-Blackfan anaemia varies considerably between affected individuals. Management approaches and individual response to available treatments influence long-term outcomes. The condition typically requires ongoing specialist haematology care throughout life.
Evidence suggests that individuals with DBA face an increased risk of developing myelodysplastic syndrome or leukaemia [PMID:22689679]. Regular surveillance for malignancy is therefore an important component of long-term care. The specific risks and appropriate monitoring strategies are discussed with families by the specialist haematology team.
Genetic causes
Diamond-Blackfan anaemia results from inherited changes in genes that encode components of ribosomes. The three causative genes identified in our reference data are RPS19, RPL5, and RPL11 [PMID:18326823]. Each of these genes provides instructions for making a ribosomal protein, which forms part of the ribosome structure.
Ribosomes translate the genetic code into proteins, a fundamental process in every living cell. These molecular machines are constructed from many individual protein components plus ribosomal RNA molecules. Defects in ribosomal protein genes compromise how efficiently new ribosomes can be assembled. Although ribosomes function throughout the body, red blood cell precursors appear uniquely vulnerable to disruption of ribosome production. The rapid cell division and intense protein synthesis required during red cell development may explain why bone marrow erythroid cells are particularly sensitive to reduced ribosome availability [PMID:22689679].
In some clinically diagnosed cases, no genetic cause is currently identified, suggesting that additional genes remain to be discovered or that some cases involve complex changes not detected by standard testing.
- RPL11 ribosomal protein L11
- RPL5 ribosomal protein L5
- RPS19 ribosomal protein S19
Inheritance pattern
Diamond-Blackfan anaemia follows an autosomal recessive inheritance pattern. An affected individual carries two copies of a pathogenic variant in the same gene - one inherited from each parent. Parents who carry one variant copy each are typically unaffected themselves, because a single functioning gene copy provides sufficient ribosomal protein for normal blood cell production.
When both parents are carriers of a variant in the same gene, each pregnancy carries a 25 per cent risk that the child will inherit both variant copies and be affected by DBA. There is a 50 per cent chance the child will inherit one variant copy and become a carrier like the parents, and a 25 per cent chance the child will inherit two typical gene copies. Genetic counselling helps families understand these recurrence risks and explore options including carrier testing for relatives, prenatal testing, or preimplantation genetic testing for couples undergoing in vitro fertilisation.
When both parents are carriers, each child has a 25% chance of being affected, 50% of being a carrier, and 25% of being unaffected.
Diagnosis & testing
Diagnosis of Diamond-Blackfan anaemia typically begins when a young infant presents with severe anaemia and characteristic blood test findings: markedly reduced red blood cells and reticulocytes (immature red cells), but normal or near-normal white blood cells and platelets. Bone marrow examination usually shows a selective absence of red cell precursors.
Genetic testing confirms the diagnosis and identifies the specific causative variant. In the NHS, suspected DBA is evaluated through the Genomic Medicine Service, often using a targeted gene panel that includes the known ribosomal protein genes. Confirmation of a genetic diagnosis enables accurate genetic counselling for the family. Clinical genetics referral is arranged through paediatric haematology services when DBA is suspected.
Management & lifestyle
Management of Diamond-Blackfan anaemia focuses on maintaining safe haemoglobin levels, monitoring for complications, and supporting quality of life. The specific treatment approach is individualised based on how each person responds to available options and the balance of benefits and risks. Long-term surveillance is an essential component of care for this lifelong condition.
Families are supported by multidisciplinary teams including paediatric and adult haematologists, clinical geneticists, genetic counsellors, and other specialists as needed. Regular monitoring includes screening for potential long-term complications. Any changes to medication or supplements should always be discussed with the specialist team, as individual circumstances vary and what suits one person may not be appropriate for another.
UK care pathway
In the UK, Diamond-Blackfan anaemia is managed through specialist paediatric haematology services with input from clinical genetics. When DBA is suspected, the child is typically referred to a regional paediatric haematology centre where confirmatory testing and initial management are coordinated. Genetic testing is accessed through the NHS Genomic Medicine Service, and relevant PanelApp panels include genes associated with inherited bone marrow failure syndromes.
Once a genetic diagnosis is confirmed, families are offered genetic counselling to discuss inheritance, recurrence risks, and implications for other family members. Long-term care often transitions to adult haematology services as the individual matures. The UK also has patient support organisations and specialist registries that help coordinate research and ensure best practice across centres. Access to specialist nurses, psychologists, and social support is an important part of comprehensive care for this lifelong condition.
Frequently asked questions
Will my child with Diamond-Blackfan anaemia need treatment for life?
Most individuals with DBA require ongoing specialist care throughout their lives. The specific treatments needed vary between individuals and may change over time. Your child's haematology team will regularly assess their condition and adjust the care plan as needed.
Can siblings or future children be tested for Diamond-Blackfan anaemia?
Yes. If a genetic variant has been identified in your affected child, siblings and other relatives can be tested to determine if they are carriers. Couples planning a pregnancy can discuss options including carrier testing, prenatal diagnosis, or preimplantation genetic testing with a genetic counsellor.
Does having Diamond-Blackfan anaemia increase cancer risk?
Evidence suggests that individuals with DBA face a higher-than-average risk of developing certain cancers, including leukaemia and some solid tumours. Your specialist team will include cancer surveillance as part of long-term follow-up to enable early detection if problems arise.
How is Diamond-Blackfan anaemia inherited if both parents are healthy?
DBA follows autosomal recessive inheritance. Both parents carry one variant copy but remain unaffected because their other gene copy functions normally. When both parents are carriers, each child has a one in four chance of inheriting both variant copies and developing DBA.
Why does Diamond-Blackfan anaemia mainly affect red blood cells if ribosomes are needed everywhere?
Although every cell needs ribosomes to make proteins, red blood cell precursors appear particularly vulnerable to ribosomal dysfunction. This may be because they multiply rapidly and require exceptionally high rates of protein production during maturation, making them more sensitive to defects in ribosome assembly.
References
- Wlodarski MW, Vlachos A, Farrar JE. Diagnosis, treatment, and surveillance of Diamond-Blackfan anaemia syndrome: international consensus statement. The Lancet. Haematology. 2024. PMID: 38697731
- Lefkopoulos S. Battling Diamond-Blackfan anaemia. Nature cell biology. 2025. PMID: 39820833
- Freedman MH. Diamond-Blackfan anaemia. Bailliere's best practice & research. Clinical haematology. 2000. PMID: 11030041
- Bartels M, Bierings M. How I manage children with Diamond-Blackfan anaemia. British journal of haematology. 2019. PMID: 30515771
- Vlachos A, Ball S, Dahl N. Diagnosing and treating Diamond Blackfan anaemia: results of an international clinical consensus conference. British journal of haematology. 2008. PMID: 18671700
- Dianzani I, Garelli E, Ramenghi U. Diamond-Blackfan Anaemia: an overview. Paediatric drugs. 2000. PMID: 11022796
- Duncan BB, Lotter JL, Superata J. Treatment of refractory/relapsed Diamond-Blackfan anaemia with eltrombopag. British journal of haematology. 2024. PMID: 38462764
- Horos R, von Lindern M. Molecular mechanisms of pathology and treatment in Diamond Blackfan Anaemia. British journal of haematology. 2012. PMID: 23016900